The short version of Albumin conjugation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
=== AI Sovereignty and National Security (2026) === In April 2026, Technology Secretary Liz Kendall delivered a landmark speech at the Royal United Services Institute (RUSI), declaring that "control over where AI systems are built, how they operate and who ultimately controls them is now fundamental to economic security, energy security and defence security". The government announced plans to develop a UK AI hardware plan to secure Britain's capability in chips and semiconductor technologies, framing AI sovereignty not as isolationism but as ensuring the UK is "indispensable" in the global AI architecture. The government also established a Sovereign AI Fund. The fund is designed to invest directly in early-stage and growth-stage British AI companies, aiming to ensure the UK remains competitive in the global AI sector. the fund is managed by Suzanne Ashman.
== Notable alumni == Debbie Boyd, politician Robin Campbell, U.S. Olympian (1980–1984) Craig Fugate, former FEMA Director Adam Kluger, advertising executive and founder of The Kluger Agency Connie Mack IV, former U.S. representative Marco Rubio, politician Jeremy Hunter, musician and composer known as Skatune Network Mallex Smith, professional baseball player Karen Thurman, former U.S. representative and chair of the Florida Democratic Party Clovis Watson Jr., politician and law enforcement officer Jonathan Zaslow, sports radio DJ and Dan Le Batard with Stugotz show host
== Development and current usage == Livia S. Eberlin, Ph.D., an Assistant Professor of Chemistry at the University of Texas at Austin, first reported the invention of the MasSpec Pen in 2017. Within her laboratory, the device has been used to analyze human tissue biopsies, including normal and cancerous breast, lung, ovarian, and thyroid samples. The MasSpec Pen is currently being evaluated for use on freshly excised tissue biopsies and for intraoperative use during oncology surgeries. The MasSpec Pen has been licensed to Genio Technologies, Inc., a subsidiary of MS Pen Technologies, Inc.
By the early 1940s, Rausing (now the sole owner of the company) began developing dairy packaging that could compete with loose milk. Erik Wallenberg, an assistant in the Åkerlund & Rausing lab, came up with the idea to construct a tetrahedron-shaped package out of a tube of paper in 1944. On 27 March 1944, Rausing filed a patent for the idea. Rausing's wife Elisabeth reportedly came up with the idea of continuously sealing the packages through the milk while filling the tube in the manner of stuffing sausages. In 1946, the company introduced the first prototype tetrahedron-package filling machine.
Sources: en.wikipedia.org
=== Subjective and objective well-being === Subjective well-being is the measure of how people feel about and evaluate their lives, encompassing both affective and cognitive components. A person has high affective well-being if they have many pleasant experiences and few unpleasant ones. High cognitive well-being occurs when a person evaluates their life positively, making a global assessment that things are going well. Subjective well-being is measured using questionnaires in which individuals report the quality of their experiences. Single-item measures provide the simplest approach, focusing on a single scale, such as asking participants to rate how content they are with their lives on a scale from 1 to 10. Multi-item scales include questions for distinct aspects of subjective well-being, with the advantage of reducing the influence of the wording of any single question. They have separate questions for domains such as the presence of positive affect, the absence of negative affect, and overall life satisfaction, which they combine into a comprehensive index. Objective well-being encompasses objective factors indicating that a person's life is going well. Unlike subjective well-being, these factors can be assessed and quantified from an external perspective. They include personal, social, economic, and environmental aspects such as health, level of education, income, housing, amount of leisure, and security. By relying on objective data, measures of objective well-being are less affected by cultural and personal biases that can influence self-reports.
==== Silver nanoparticles ==== Silver compounds and silver ions also have been known to show antimicrobial properties and are used in many applications, including water treatment. It is shown that silver ions prevent DNA replication and affect the structure and permeability of the cell membrane. Silver also leads to UV inactivation of bacteria and viruses because silver ions are photoactive in the presence of UV-A and UV-C irradiation. Cysteine and silver ions form a complex that leads to the inactivation of Haemophilus influenzae phage and bacteriophage MS2.
Ice thickness monitoring: This can be done using drill holes or using ground-penetrating radar. Trafficability monitoring: The ice surface can deteriorate with usage. It can also get damaged by natural processes, such as ridging and fracturing, which are typically induced by sharp changes in air temperature.
Gonadotropin receptors are embedded in the surface of the target cell membranes and coupled to the G-protein system. Signals triggered by binding to the receptor are relayed within the cells by the cyclic AMP second messenger system. Gonadotropins are released under the control of gonadotropin-releasing hormone (GnRH) from the arcuate nucleus and preoptic area of the hypothalamus. The gonads — testes and ovaries — are the primary target organs for LH and FSH. The gonadotropins affect multiple cell types and elicit multiple responses from the target organs. As a simplified generalization, LH stimulates the Leydig cells of the testes and the theca cells of the ovaries to produce testosterone (and indirectly estradiol), whereas FSH stimulates the spermatogenic tissue of the testes and the granulosa cells of ovarian follicles, as well as stimulating production of estrogen by the ovaries. Although gonadotropins are secreted in a pulsatile manner (as a result of pulsatile GnRH release), unlike the case of GnRH and GnRH agonists, constant/non-pulsatile activation of the gonadotropin receptors by the gonadotropins does not produce functional inhibition. This can be seen during the first 7–10 weeks of pregnancy, where constantly high and progressively-increasing levels of hCG circulate and mediate production of estrogen and progesterone by the corpus luteum until the placenta takes over the production of these hormones.
Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan.
Sources: en.wikipedia.org
=== Overdose === Overdose most often causes slow heart rate. Respiratory depression, low blood pressure, constricted pupils, hypothermia, brief episodes of high blood pressure, drowsiness, headaches and vomiting may also occur. In serious cases some of these effects may result in circulatory shock. Most often overdoses occur in children who have ingested the drug. There is no antidote for tetryzoline or other similar imidazoline analogue poisoning, but the symptoms can be alleviated. With treatment, death is rare.
=== BsAbs on the market === Several bispecific antibodies are presently in clinical use. Blinatumomab, which targets CD19 and CD3, is used in the treatment of Philadelphia chromosome negative B cell acute lymphoblastic leukemia (ALL). Emicizumab, which targets clotting factors IXa and X, is used in the treatment of hemophilia A. Catumaxomab was withdrawn from the European market in 2017 for commercial reasons. Amivantamab, which targets epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Teclistamab, which targets CD3 and B-cell maturation antigen (BCMA), is used in the treatment of multiple myeloma, and zenocutuzumab.
Superheated water can be used to chemically convert organic material into fuel products. This is known by several terms, including direct hydrothermal liquefaction, and hydrous pyrolysis. A few commercial scale applications exist. Thermal depolymerization or thermal conversion (TCC) uses superheated water at about 250 °C to convert turkey waste into a light fuel oil and is said to process 200 tons of low grade waste into fuel oil a day.
=== mEos4 === Many new monomeric versions of EosFP have been developed that offer advantages over wild type EosFP. Developed by a team at the Janelia Farm Research Campus at Howard Hughes Medical Institute, mEos4 has higher photostability and longer imaging abilities than EosFP. It is also highly resistant to chemical fixatives such as PFA, gluteraldehyde and OsO4 which are used to preserve samples. mEos4 is effective at higher temperatures than EosFP, phot-converts at an increased rate and has a higher emission amplitude in both green and red fluorescent states. Applications for the mEos4 protein include photoactivation localization microscopy (PALM), correlative light/ electron microscopy (CLEM), protein activity indication and activity integration (post-hoc imaging for protein activity over time).
== Chromatography == Mikhail Tsvet invented chromatography in 1900 during his research on plant pigments. He used liquid-adsorption column chromatography with calcium carbonate as adsorbent and petrol ether/ethanol mixtures as eluent to separate chlorophylls and carotenoids. The method was described on 30 December 1901 at the XI Congress of Naturalists and Physicians (XI съезд естествоиспытателей и врачей) in St. Petersburg. The first printed description was in 1905, in the Proceedings of the Warsaw Society of Naturalists, biology section. He first used the term "chromatography" in print in 1906 in his two papers about chlorophyll in the German botanical journal, Berichte der Deutschen botanischen Gesellschaft. In 1907, he demonstrated his chromatograph for the German Botanical Society. For several reasons, Tsvet's work was long ignored: the violent political upheaval in Russia at the beginning of the 20th century, the fact that Tsvet originally published only in Russian (making his results largely inaccessible to western scientists), and an article denying Tsvet's findings. Richard Willstätter and Arthur Stoll tried to repeat Tsvet's experiments, but because they used an overly aggressive adsorbent (destroying the chlorophyll), they were not able to do so. They published their results, and Tsvet's chromatography method fell into obscurity. It was revived 10 years after his death thanks to Austrian biochemist Richard Kuhn and his student, German scientist Edgar Lederer as well as the work of A. J. Martin and R. L. Synge.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.